Iterum Therapeutics PLC

NASDAQ ITRM

Data sourced from iex and EODHD
Download Data

Iterum Therapeutics PLC Operating Cash Flow for the quarter ending March 31, 2024: USD -13.08 M

Iterum Therapeutics PLC Operating Cash Flow is USD -13.08 M for the quarter ending March 31, 2024, a -36.42% change year over year. Operating Cash Flow is the net cash generated from a company's core operations, including revenue, expenses, and changes in working capital.
  • Iterum Therapeutics PLC Operating Cash Flow for the quarter ending March 31, 2023 was USD -9.59 M, a -181.64% change year over year.
  • Iterum Therapeutics PLC Operating Cash Flow for the quarter ending March 31, 2022 was USD -3.40 M, a -200.80% change year over year.
  • Iterum Therapeutics PLC Operating Cash Flow for the quarter ending March 31, 2021 was USD -1.13 M, a 95.87% change year over year.
  • Iterum Therapeutics PLC Operating Cash Flow for the quarter ending March 31, 2020 was USD -27.39 M, a -81.96% change year over year.
NASDAQ: ITRM

Iterum Therapeutics PLC

CEO Mr. Corey N. Fishman
IPO Date May 25, 2018
Location Ireland
Headquarters Fitzwilliam Court, Dublin, Ireland, 2
Employees 14
Sector Healthcare
Industry Biotechnology
Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Similar companies

HOTH

Hoth Therapeutics Inc

NA

NA

StockViz Staff

September 16, 2024

Any question? Send us an email